I
Innate Pharma
Clinical-stage biotechnology company dedicated to improving cancer treatment and clinical outcomes for patients through first-in-class therapeutic antibodies that harness the innate immune system
About Innate Pharma
Innate Pharma operates in the biopharmaceutical sector, focusing on the development of immunotherapy drugs for cancer treatment. The company specializes in creating NK cell engagers, which are designed to harness the body's natural immune response to target and destroy cancer cells. Innate Pharma collaborates with major pharmaceutical companies, such as Sanofi, to advance its drug candidates through clinical development. The business model involves research and development, followed by strategic partnerships and licensing agreements to commercialize its therapies. Revenue is generated through milestone payments and royalties from these collaborations. Innate Pharma primarily serves the oncology market, aiming to provide innovative solutions for unmet medical needs in cancer care. The company is publicly traded on Euronext Paris, which provides it with access to capital markets to fund its research initiatives. Keywords: biopharmaceutical, immunotherapy, cancer, NK cell engagers, oncology, drug development, partnerships, licensing, milestone payments, Euronext Paris.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 1999
- Headquarters
- Marseille, France
- Listing
- IPO 2015
- Employees
- 176
- Open positions
- None listed
- Dealroom signal
- 63.9/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Drug Development, Biotech and Pharma, biotech medtech and e-health, Observatoire Deeptech, Hard Tech, Horizon Europe, participations bpifrance
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO EQUITY✓Other financing | Aug 2026 | $33M | — | Bpifrance | ↗ |
| POST IPO EQUITY✓Other financing | Apr 2025 | $16M | — | Sanofi | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Innate Pharma is 9.2K monthly website visits, down 23.3% over the last three months. Innate Pharma's team declined 10.2% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A6 investors entered at this stage
Sofinnova Partners
Auriga Partners
Gimv
Ardian
Akka Venture
Gilde Healthcare
Series B and later6 investors entered at this stage
Novo Nordisk
Tikehau Ace Capital
Redmile Group
The Institute for Follicular Lymphoma Innovation
Sanofi
Bpifrance
Other known investors1 additional known investor
Auriga Partners (Paris)
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Innate Pharma on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Innate Pharma’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.